Lancet Oncol: Long-term outcomes of pembrolizumab vs chemotherapy in metastatic colorectal cancer with high microsatellite instability/mismatch repair deficiency

Compared with chemotherapy, pembrolizumab prolonged progression-free survival in patients with newly diagnosed metastatic colorectal cancer with high microsatellite instability or positive mismatch repair deficiency

The KEYNOTE-177 study is a randomized, open-label Phase 3 clinical trial conducted at 193 medical centers in multiple countries, enrolling patients 18 years of age and older, ECOG performance status 0-1, and previously untreated microsatellites Patients with metastatic colorectal cancer with high instability or positive mismatch repair deficiency

Between February 11, 2016, and February 19, 2018, a total of 852 patients were screened , of whom 307 (36%) were randomized to pembrolizumab (n=153) or chemotherapy (n=154) )

In conclusion, although pembrolizumab demonstrated durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two groups

Original source:

Diaz Luis A, Shiu Kai-Keen, Kim Tae-Won et al.